EUVIMEDEUVIMED entdecken
Open Access

Blinatumomab administration in the outpatient setting: Safety and health care utilization

Yannis K Valtis iD, Benjamin F Frost, David Nemirovsky, Andriy Derkach, Kuo-Kai Chin, Meira Yisraeli Salman iD, Leora Boussi iD, Natalia Tijaro Ovalle iD, Emilie Baxter, Ann Mercurio iD, Eytan M Stein, Mark B Geyer und 6 weitere

Cancer · 15.08.2026 · 132 (16)

DOI: 10.1002/cncr.70566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 18.08.2026. Verfasst von Yannis K Valtis und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Patient Acceptance of Health Care, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, American Society of Hematology, Conquer Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B‐cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (FDA) recommends preemptive hospitalization for the initiation of cycle 1 (C1) and cycle 2 (C2). The necessity of this approach is unclear.

Methods

The authors conducted a retrospective cohort study among all patients treated with blinatumomab between 2012 and 2025 at two academic cancer centers: Memorial Sloan Kettering Cancer Center (MSK) and Dana‐Farber Cancer Institute (DFCI).

Results

For C1, only nine of 308 (3%) patients initiated outpatient (OP) treatment. A total of 184 of 308 (60%) initiated C2: At DFCI, 10 of 83 (12%) initiated C2 OP and at MSK, and 74 of 101 (88%) initiated C2 OP. Demographic and clinical characteristics were similar between patients initiating C2 inpatient versus OP. No patients who initiated C2 (0 of 184) had Gr3+ CRS (across all cycles) and only two (1%) had Gr3+ ICANS; both were inpatient for C2. Of 84 patients treated without preemptive hospitalization for C2, 16 of 84 (19%) required hospitalization at some point during the cycle, largely for infections (50%).

Conclusions

OP administration of C2 of blinatumomab can be administered safely with no unexpected, severe, or life‐threatening toxicities. The ability to safely manage treatment without preemptive hospitalization may support the patient experience and limit costs of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificPatient Acceptance of Health CarePrecursor Cell Lymphoblastic Leukemia-LymphomaHumansFemaleRetrospective StudiesMaleMiddle AgedAdultAgedAmbulatory CareAdolescentOutpatientsYoung Adult

Stichwörter der Autor:innen

health resourceshealth serviceshematologic neoplasmsimmunotherapyleukemia

Substanzen

Antibodies, Bispecificblinatumomab

Autor:innen und Institutionen

  • Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Yannis K Valtis, Meira Yisraeli Salman, Leora Boussi, Natalia Tijaro Ovalle, Ann Mercurio, Marlise R Luskin

Förderung

  • NCI NIH HHS
  • American Society of Hematology
  • Conquer Cancer Foundation

Zitieren

APA

Valtis, Y. K., Frost, B. F., Nemirovsky, D., Derkach, A., Chin, K. K., Salman, M. Y., Boussi, L., Ovalle, N. T., Baxter, E., Mercurio, A., Stein, E. M., Geyer, M. B., Schrag, D., Kelkar, A. H., DeAngelo, D. J., Luskin, M. R., Park, J. H., & Chen, E. C. (2026). Blinatumomab administration in the outpatient setting: Safety and health care utilization. Cancer, 132(16). https://doi.org/10.1002/cncr.70566

Vancouver

Valtis YK, Frost BF, Nemirovsky D, Derkach A, Chin KK, Salman MY, et al. Blinatumomab administration in the outpatient setting: Safety and health care utilization. Cancer. 2026;132(16). doi:10.1002/cncr.70566

BibTeX
@article{Valtis2026,
  author = {Valtis, Yannis K and Frost, Benjamin F and Nemirovsky, David and Derkach, Andriy and Chin, Kuo-Kai and Salman, Meira Yisraeli and Boussi, Leora and Ovalle, Natalia Tijaro and Baxter, Emilie and Mercurio, Ann and Stein, Eytan M and Geyer, Mark B and Schrag, Deborah and Kelkar, Amar H and DeAngelo, Daniel J and Luskin, Marlise R and Park, Jae H and Chen, Evan C},
  title = {Blinatumomab administration in the outpatient setting: Safety and health care utilization},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {16},
  doi = {10.1002/cncr.70566}
}
Kostenlos starten →